Tonix Pharmaceuticals (NASDAQ:TNXP) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research report report published on Thursday. The brokerage issued a sell rating on the stock.

Tonix Pharmaceuticals Price Performance

Shares of TNXP stock opened at $0.19 on Thursday. Tonix Pharmaceuticals has a fifty-two week low of $0.12 and a fifty-two week high of $22.14. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The firm has a market capitalization of $35.51 million, a price-to-earnings ratio of 0.00 and a beta of 2.06. The stock’s 50-day simple moving average is $0.15 and its 200-day simple moving average is $1.18.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The business had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. As a group, equities analysts forecast that Tonix Pharmaceuticals will post -18 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Acadian Asset Management LLC increased its holdings in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 335,373 shares of the company’s stock after buying an additional 242,358 shares during the quarter. Acadian Asset Management LLC owned about 0.40% of Tonix Pharmaceuticals worth $61,000 at the end of the most recent reporting period. 82.26% of the stock is currently owned by institutional investors and hedge funds.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.